S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling

Pingping Luo,Ming Zheng,Rui Zhang,Hong Zhang,Yingxia Liu,Wei Li,Xiaoming Sun,Qian Yu,George L. Tipoe,Jia Xiao
DOI: https://doi.org/10.1016/j.apsb.2020.11.006
IF: 14.903
2021-03-01
Acta Pharmaceutica Sinica B
Abstract:<p>Alcoholic liver disease (ALD) causes insulin resistance, lipid metabolism dysfunction, and inflammation. We investigated the protective effects and direct regulating target of <em>S</em>-allylmercaptocysteine (SAMC) from aged garlic on liver cell injury. A chronic ethanol-fed ALD <em>in vivo</em> model (the NIAAA model) was used to test the protective functions of SAMC. It was observed that SAMC (300 mg/kg, by gavage method) effectively ameliorated ALD-induced body weight reduction, steatosis, insulin resistance, and inflammation without affecting the health status of the control mice, as demonstrated by histological, biochemical and molecular biology assays. By using biophysical assays and molecular docking, we demonstrated that SAMC directly targeted insulin receptor (INSR) protein on the cell membrane and then restored downstream IRS-1/AKT/GSK3<em>β</em> signaling. Liver-specific knock-down in mice and siRNA-mediated knock-down in AML-12 cells of <em>Insr</em> significantly impaired SAMC (250 μmol/L in cells)-mediated protection. Restoration of the IRS-1/AKT signaling partly recovered hepatic injury and further contributed to SAMC's beneficial effects. Continuous administration of AKT agonist and recombinant IGF-1 in combination with SAMC showed hepato-protection in mice model. Long-term (90-day) administration of SAMC had no obvious adverse effect on healthy mice. We conclude that SAMC is an effective and safe hepato-protective complimentary agent against ALD partly through the direct binding of INSR and partial regulation of the IRS-1/AKT/GSK3<em>β</em> pathway.</p>
pharmacology & pharmacy
What problem does this paper attempt to address?